broker. das der markt da ist, bestreitet auch keiner, nur muß eben auch ein produkt da sein, was der auf dem markt der renner wird.
derzeit muß ich zu allen aidsberichten sagen: schön und gut, aber was wird aus caly? trinity wird da schön verkaufen und orasure wohl auch. hier dei letzten zahlen von orasure. die erlöse werden immer höher und auch orasure hat bald den break-even erreicht. auch sie profitieren wie trinity vom wachsenden markt. nur calys zahlen bleiben grottenschlecht. die meldung ist zwar schon vom 10.02.05 aber bezeichnend für calys wachsendes desaster aufgrund verlorener zeit:
OraSure Announces Record Financial Results
BETHLEHEM, Pa., Feb 10, 2005 (BUSINESS WIRE) -- OraSure Technologies, Inc.
(NASDAQ: OSUR), the market leader in oral fluid diagnostics, today announced
record revenues of $54.0 million and $14.2 million for the year and quarter
ended December 31, 2004, respectively. Full year 2004 revenues represent a 34%
increase from the $40.5 million in revenues recorded for 2003. Revenues for the
quarter ended December 31, 2004 were 20% higher than those for the same period
of 2003.
The Company also reported a net loss of $0.6 million, or $(0.01) per share, for
the full year 2004, and a net loss of $245,000, or $(0.01) per share, for the
fourth quarter of 2004. This compares to a net loss of $1.1 million, or $(0.03)
per share and a profit of $435,000, or $0.01 per share, for the full year and
quarter ended December 31, 2003, respectively.
"We are very pleased with the Company's fourth quarter results leading to a
tenth consecutive quarter of record revenues," said Douglas A. Michels,
President and CEO of OraSure Technologies. "Each of our product lines continued
to experience growth in the fourth quarter with notable gains in Substance Abuse
Testing and Cryosurgical Systems. Our performance in 2004 has put us in position
for great success in 2005 and beyond."
The increase in 2004 full year revenues was primarily the result of increased
sales of the Company's Freeze Off(TM) wart removal product, OraQuick(R) rapid
HIV antibody tests, and Intercept(R) oral fluid drug testing system. These
increases were partially offset by a decline in sales of assays in the insurance
risk assessment market. Product revenues were a record $53.6 million for the
full year 2004 and a record $14.1 million for the quarter ended December 31,
2004, representing increases of 35% and 20%, respectively, over the comparable
2003 periods.
ABBOTT PARK, Ill., and BETHLEHEM, Pa., Feb 14, 2005 /PRNewswire-FirstCall via
COMTEX/ -- Abbott (NYSE: ABT) and OraSure Technologies (Nasdaq: OSUR) today
announced an agreement for the distribution of OraSure Technologies' OraQuick(R)
ADVANCE(TM) rapid antibody test for the detection of antibodies to the Human
Immunodeficiency Virus Type 1 (HIV-1) and Type 2 (HIV-2). Under the terms of the
distribution agreement, Abbott was appointed as exclusive distributor of the
OraQuick(R) ADVANCE(TM) HIV-1/2 test for hospitals and as a non-exclusive
distributor to physician offices in the United States.
"We believe this agreement will enable us to capitalize on the growing demand
for our new OraQuick(R) ADVANCE(TM) test and help achieve our goal of making
rapid HIV testing available to all who need it," said Douglas A. Michels,
President and CEO of OraSure Technologies. "With the sales and marketing teams
from OraSure and Abbott working together, we will expand the reach of this
product in the United States."
Providing results in as little as 20 minutes, OraQuick(R) ADVANCE(TM) is the
only rapid, point-of-care test for the detection of antibodies to both HIV-1 and
HIV-2 approved by the U.S. Food and Drug Administration (FDA) for use on oral
fluid, finger stick or venipuncture whole blood, and plasma specimens. The test
is also CLIA (Clinical Laboratory Improvements Amendments Act of 1988) waived
for all specimen types except plasma. OraSure commercially launched the
OraQuick(R) ADVANCE(TM) test in October 2004.
Thread abonnieren
